HIBOC = Hepatic Imaging Biomarkers in Obese Children

Launched by SAHLGRENSKA UNIVERSITY HOSPITAL · Jun 12, 2024

Keywords

ClinConnect Summary

The HIBOC trial, which stands for Hepatic Imaging Biomarkers in Obese Children, is studying how imaging tests can help doctors understand liver disease in children who are obese. The researchers want to find out if special ultrasound and MRI techniques can be useful tools for diagnosing liver issues in these children. They will look at how these imaging results relate to other important health measures, like body mass index (BMI) and blood tests, and how they change with treatment over time.

To be part of this study, children aged 9 to 14 years who have a BMI of 30 or higher and have been obese for over a year may be eligible. The study is not yet recruiting participants, but it will take place at clinics that focus on child and adolescent health. Children who have difficulty understanding information, have certain liver-related health conditions, experience claustrophobia, or have implants that prevent them from having an MRI will not be able to participate. If eligible, participants can expect to undergo imaging tests that will help researchers learn more about the relationship between obesity and liver health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 9 to 14 years
• • New referral/first visit or follow-up annual visit at each healthcare center (Child and adolescent oriented centers) included
• • BMI 30 or more
• • Obesity \>1 year at inclusion
• Exclusion Criteria:
• • Difficulty understanding written/oral information
• • Comorbidities that can affect the liver (e.g., medications or diseases with known liver impact)
• • Claustrophobia (applies to the MRI cohort)
• • Implants or other factors that prevent MRI (applies to the MRI cohort)